Insulin News and Research

RSS

Insulin is a hormone that is needed to convert glucose, starches and other food into energy needed for daily life. Insulin allows cells to use glucose for fuel and is secreted by beta cells in the islets of Langerhans. The release of insulin from the pancreas is stimulated by increased blood glucose, vagal nerve stimulation, and other factors. Insulin is obtained from various animals and available in a variety of preparations. Commercial insulin preparations differ in a number of ways, including differences in the animal species from which they are obtained; their purity, concentration, and solubility; and the time of onset and duration of their biologic action. An oral hypoglycemic agent is not a form of insulin therapy.

Karolinska Institutet to study fundamental causes of diabetes

The Swedish medical university, Karolinska Institutet, has received a grant of 1.6 million Euro from the Stichting af Jochnick Foundation for research into the fundamental causes of diabetes. The grant will make it possible to use unique methods to study how the release of insulin is regulated in living organisms - and this will create new opportunities for developing more effective drugs against diabetes.

7 Feb 2012

Diabetic mothers and risk of birth defects in baby: Study

Anew study published in Diabetologica reveals that pregnant women with diabetes are almost four times more likely to have a baby with a birth defect.

6 Feb 2012

Exercise under hypoxic conditions provides improvements in glycemic control

Intermittent exercise with and without low oxygen concentrations (or hypoxia) can improve insulin sensitivity in type 2 diabetics, however exercise while under hypoxic conditions provides greater improvements in glycemic control than intermittent exercise alone, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

3 Feb 2012

Merck receives FDA approval for JANUMET XR to treat type 2 diabetes

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration approved JANUMET XR (sitagliptin and metformin hydrochloride extended-release) tablets, a new treatment for type 2 diabetes that combines sitagliptin, which is the active component of JANUVIA (sitagliptin), with extended-release metformin.

3 Feb 2012

Researchers reveal how antipsychotics affect metabolism by SMAD3 activation

In a paper published January 31 in the journal Molecular Psychiatry, researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham) reveal how antipsychotic drugs interfere with normal metabolism by activating a protein called SMAD3, an important part of the transforming growth factor beta (TGFbeta) pathway.

2 Feb 2012

Reduced insulin sensitivity linked to smaller brain size, deteriorated language skills in seniors

New research from Uppsala University shows that reduced insulin sensitivity is linked to smaller brain size and deteriorated language skills in seniors. The findings are now published in the scientific journal Diabetes Care.

2 Feb 2012

Brief 10-minute massage helps reduce inflammation in muscle

Researchers at McMaster University have discovered a brief 10-minute massage helps reduce inflammation in muscle.

1 Feb 2012

Decaffeinated coffee may improve brain energy metabolism linked with type 2 diabetes

Researchers from Mount Sinai School of Medicine have discovered that decaffeinated coffee may improve brain energy metabolism associated with type 2 diabetes.

1 Feb 2012

Boehringer Ingelheim, Lilly receive FDA approval for Jentadueto to treat type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved Jentadueto (linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin.

31 Jan 2012

Bioton and Actavis form joint venture

Actavis and Bioton announced today that they have formed a joint venture company for the development and registration of insulins, including analogue insulins.

31 Jan 2012

MT2 gene mutations may increase risk of diabetes

Researchers in Lille and Paris demonstrated that mutations in the melatonin receptor gene (melatonin or the "hormone of darkness" induces sleep) lead to an almost sevenfold increase in the risk of developing diabetes.

31 Jan 2012

Blood sugar self-monitoring has no benefit for diabetics not on insulin

For type 2 diabetics who are not on insulin, monitoring their blood sugar does little to control blood sugar levels over time and may not be worth the effort or expense, according to a new evidence review.

30 Jan 2012

Researchers develop new physical form of proteins to improve treatments for cancer

A new physical form of proteins developed by researchers at The University of Texas at Austin could drastically improve treatments for cancer and other diseases, as well as overcome some of the largest challenges in therapeutics: delivering drugs to patients safely, easily and more effectively.

30 Jan 2012

Study finds link between body clock hormone melatonin, type 2 diabetes

A study published in Nature Genetics today has found new evidence for a link between the body clock hormone melatonin and type 2 diabetes. The study found that people who carry rare genetic mutations in the receptor for melatonin have a much higher risk of type 2 diabetes.

30 Jan 2012

Oramed receives Australian patent for core technology in oral delivery of peptides

Marking a major milestone for the Company, Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it has received approval for a key patent by the Australian Patent Office.

25 Jan 2012

Link between high fructose intake and cardiovascular risk in adolescents

Evidence of cardiovascular disease and diabetes risk is present in the blood of adolescents who consume a lot of fructose, a scenario that worsens in the face of excess belly fat, researchers report.

25 Jan 2012

Echo commences Symphony tCGM System trials in critical care patients

Echo Therapeutics, Inc., a company developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude SkinPrep System for transdermal drug delivery, today announced that it is initiating clinical studies of its Symphony tCGM System in critical care patients.

25 Jan 2012

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

Johnson & Johnson today announced sales of $16.3 billion for the fourth quarter of 2011, an increase of 3.9% as compared to the fourth quarter of 2010. Operational sales increased 4.0% and the negative impact of currency was 0.1%.

24 Jan 2012

Novo Nordisk Type 1 Diabetes R&D Center to be established in Seattle

Novo Nordisk announced today that the company will establish a type 1 diabetes research and development center in Seattle, Wash., U.S. The new center will combine Novo Nordisk's history of innovation and leadership in diabetes treatment with the company's growing expertise in immunotherapy.

24 Jan 2012

Luteolin interferes with cell signaling in colon cancer cells

Luteolin is a flavonoid commonly found in fruit and vegetables. This compound has been shown in laboratory conditions to have anti-inflammatory, anti-oxidant and anti-cancer properties but results from epidemiological studies have been less certain. New research published in BioMed Central's open access journal BMC Gastroenterology shows that luteolin is able to inhibit the activity of cell signaling pathways (IGF and PI3K) important for the growth of cancer in colon cancer cells.

23 Jan 2012